Coimbra Genomics Company

Coimbra Genomics, S.A. has developed and is commercializing ELSIE, a first-in-class digital platform that allows physicians of any speciality to use information on their patient’s genome during a regular medical appointment. By combining the capacity to provide fast, accurate, on-the-spot answers based on each patient’s genome with an efficient articulation with multiple providers of specific genetic tests, ELSIE is the first simple, highly scalable and completely secure way to perform personalized medicine.

Technology: Others
Headquarters: Cantanhede, Coimbra, Portugal
Total Funding: €4.7M
Last Funding Type: Series A
Founded Date: 2013-01-01
Investors Number: 3
Industry: Biotechnology, Health Care, Science and Engineering
Employee Number: 1-10
Estimated Revenue: $1M to $10M
Investor Type: For Profit
Funding Status: Early Stage Venture